Insiders Are Spending Big: 15 Stocks Leading in March

4. Janux Therapeutics, Inc. (NASDAQ:JANX)

Total Value of Insider Purchases in March: $25.34 million

Market Capitalization: $1.83 billion

Janux Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapies using its TRACTr and TRACIr platform technologies. Its clinical candidates include JANX007 for metastatic castration-resistant prostate cancer and JANX008 for various solid cancers, both in Phase 1 trials. The San Diego, California-based company collaborates with Merck Sharp & Dohme Corp. to develop its TRACTr therapies.

For the full year 2024, the company disclosed a net loss of $69.0 million, compared to $58.3 million in 2023. Research and development expenses were $68.4 million, which compares to $54.9 million for 2023. As of December 31, 2024, Janux reported cash and cash equivalents and short-term investments of $1.03 billion compared to $344.0 million on December 31, 2023.

In March, one insider bought $25.34 million worth of Janux Therapeutics shares at an average price of $30.92 per share. The stock trades at $30.91 per share, down 42.27% year-to-date and 21.01% over the past 12 months.

According to StockAnalysis, 10 analysts rate Janux Therapeutics stock as a “Strong Buy,” with a 12-month price target of $84.00, up 171.76% from its current price.

Janux Therapeutics is also among the 10 worst high-risk high-reward growth stocks to buy.